Prodromal Clinical Markers of Parkinson disease in Gaucher Disease Individuals

European Neurology

Volumn 76, Issue 1-2, 2016, Pages 19-21

  Gatto, Emilia M ^a   Etcheverry, Jose Luis ^a   Sanguinetti, Ana ^a   Cesarini, Martin ^a   Fernandez Escobar, Nicolas ^b   Drelichman, Guillermo ^b  

^a INEBA ^*  (Argentina)

^b HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HYMECROMONE; TAUROCHOLIC ACID; GLUCOSYLCERAMIDASE;

ADOLESCENT; ADULT; ARGENTINA; ARTICLE; BEHAVIOR DISORDER; CHILD; CLINICAL ARTICLE; COGNITIVE DEFECT; COHORT ANALYSIS; CONSTIPATION; DEPRESSION; ENZYME ACTIVITY; ENZYME THERAPY; FEMALE; GAUCHER DISEASE; HUMAN; HYPOSMIA; MALE; MONTREAL COGNITIVE ASSESSMENT; NEUROLOGIC EXAMINATION; PARASOMNIA; PARKINSON DISEASE; PRIORITY JOURNAL; REM SLEEP; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; COMPLICATION; ENZYME REPLACEMENT; GENETICS; HETEROZYGOTE; MIDDLE AGED; MUTATION; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; BIOMARKERS; CHILD; ENZYME REPLACEMENT THERAPY; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; RISK FACTORS; YOUNG ADULT;

EID: 84976597028     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000447510     Document Type: Article

References (17)

1. Huang WJ, Zhang X, Chen WW: Gaucher disease: a lysosomal neurodegenerative disorder. Eur Rev Med Pharmacol Sci 2015; 19: 1219-1226.
2. Pal G, Robertson E, O'Keefe J, Hall D: The neuropsychiatric and motor profile of GBAassociated Parkinson's disease: a review. Mov Disord Clin Pract 2016; 3: 4-8.
3. Zokaei N, McNeill A, Proukakis C, Beavan M, Jarman P, et al: Visual short-term memory deficits associated with GBA mutation and Parkinson's disease. Brain 2014; 137(pt 8):2303-2311.
4. Mitsui J, Matsukawa T, Sasaki H, Yabe I, Matsushima M, et al: Variants associated with Gaucher disease in multiple system atrophy. Ann Clin Transl Neurol 2015; 2: 417-426.
5. Schapira AH: Glucocerebrosidase and Parkinson disease: recent advances. Mol Cell Neurosci 2015; 66(pt A):37-42.
6. Beavan M, McNeill A, Proukakis C, Hughes DA, Mehta A, Schapira AH: Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort. JAMA Neurol 2015; 72: 201-208.
7. Chamoles NA, Blanco M, Gaggioli D, Casentini C: Gaucher and Niemann-Pick diseases-enzymatic diagnosis in dried blood spots on filter paper: retrospective diagnoses in newborn-screening cards. Clin Chim Acta 2002; 317: 191-197.
8. Raghavan SS, Topol J, Kolodny EH: Leukocyte beta-glucosidase in homozygotes and heterozygotes for Gaucher disease. Am J Hum Genet 1980; 32: 158-173.
9. Postuma RB, Arnulf I, Hogl B, Iranzo A, Miyamoto T, Dauvilliers Y, et al: A single-question screen for rapid eye movement sleep behavior disorder: a multicenter validation study. Mov Disord 2012; 27: 913-916.
10. Millar Vernetti P, Perez Lloret S, Rossi M, Cerquetti D, Merello M: Validation of a new scale to assess olfactory dysfunction in patients with Parkinson's disease. Parkinsonism Relat Disord 2012; 18: 358-361.
11. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al; Movement Disorder Society UPDRS Revision Task Force: Movement disorder society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 15: 2129-2170.
12. Fulda S, Hornyak M, Muller K, Cerny L, Beitinger P, Wetter T: Development and validation of the Munich Parasomnia Screening (MUPS). Somnologie 2008; 12: 56-65.
13. Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
14. Grabowski GA, Zimran A, Ida H: Gaucher disease types 1 and 3: phenotypic characterization of large populations from the ICGG Gaucher registry. Am J Hematol 2015; 90(suppl 1):S12-S18.
15. Lopez G, Monestime G, Sidransky E: Clinical studies of GBA1-associated Parkinsonism: progress and challenges. Neurodegener Dis Manag 2016; 6: 1-4.
16. Lopez G, Kim J, Wiggs E, Cintron D, Groden C, Tayebi N, et al: Clinical course and prognosis in patients with Gaucher disease and Parkinsonism. Neurol Genet 2016; 2:e57.
17. McNeill A, Magalhaes J, Shen C, Chau KY, Hughes D, Mehta A, Foltynie T, Cooper JM, Abramov AY, Gegg M, Schapira AH: Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 2014; 137(pt 5):1481-1495.